Year All202620252024202320222021202020192018 March 17, 2026 Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update February 23, 2026 Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension January 8, 2026 Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Year All202620252024202320222021202020192018 March 17, 2026 Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update February 23, 2026 Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension January 8, 2026 Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
